N/A
Completed N=185
Retrospective Data Collection: Post Study Treatment Anticancer Therapy From IMELDA MO22223
Source: ClinicalTrials.gov NCT02383576 ↗Enrolled (actual)
185
Serious AEs
—
Results posted
Apr 2018
Primary outcomePrimary: Percentage of Participants Who Prematurely Withdrawn From Maintenance Therapy — 93.2; 84.7 percentage of participants
Summary
This study aims to understand better the effective results from the IMELDA MO22223 P-trial (NCT00929240) and see if the anti-cancer therapies given during its follow-up time after study treatments were terminated possibly had an effect on efficacy results.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage of Participants Who Prematurely Withdrawn From Maintenance Therapy |
93.2; 84.7 | — |
| PRIMARY Percentage of Participants Who Received Further Anti-Cancer Therapies After Discontinuation of Study Treatment |
94.9; 91.5 | — |
| PRIMARY Time From Last Maintenance Study Medication Start to Start of Further Anti-Cancer Therapy |
22.5; 23.5 | — |
| PRIMARY Progression Free Survival (PFS) |
4.3; 12.2 | — |
| PRIMARY Overall Survival |
22.3; 36.5 | — |
Eligibility Criteria
Inclusion Criteria
Having been randomized in the IMELDA MO22223 P-trial
Exclusion Criteria
Not having been randomized in the IMELDA MO22223 P-trial
Data sourced from ClinicalTrials.gov (NCT02383576). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.